Article
Ophthalmology
Mathew W. Maccumber, Charles C. Wykoff, Helene Karcher, Eser Adiguzel, Samriddhi Buxy Sinha, Saloni Vishwakarma, Andrew Laprise, Franklin Igwe, Rita Freitas, Michael S. Ip, Marco A. Zarbin
Summary: This community-based study demonstrates that brolucizumab treatment can prolong injection intervals between treatment-experienced eyes and maintain or improve visual acuity, especially for eyes with shorter intervals before switching.
Article
Medicine, General & Internal
Pasquale Viggiano, Maria Oliva Grassi, Giacomo Boscia, Mariagrazia Pignataro, Giovanni Petruzzella, Enrico Borrelli, Teresa Molfetta, Giovanni Alessio, Francesco Boscia
Summary: The study explores the morphofunctional fluctuations in eyes treated for neovascular AMD when switching from aflibercept or ranibizumab to brolucizumab. The results showed that brolucizumab treatment improved visual function in patients and resulted in choroidal vascular enlargement and resolution of subretinal and intraretinal fluid.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Alaa Din Abdin, Wissam Aljundi, Khalil El Jawhari, Shady Suffo, Isabel Weinstein, Berthold Seitz
Summary: The study aimed to evaluate the morphological and functional outcomes of intravitreal brolucizumab treatment for refractory neovascular age-related macular degeneration (nAMD) in the first year. Results showed that brolucizumab could stabilize visual acuity and reduce the number of injections. It also improved anatomical outcomes by reducing subretinal fluid and pigment epithelial detachment. However, adverse events such as intraocular inflammation were observed.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Alper Bilgic, Laurent Kodjikian, Shail Vasavada, Shyamal Jha, Samaresh Srivastava, Aditya Sudhalkar, Thibaud Mathis
Summary: The study found that brolucizumab demonstrated significant efficacy in managing CNV patients with RPE tears and subretinal fluid, showing substantial improvements in visual and anatomical outcomes without complications during one-year follow-up.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Ophthalmology
Pravin U. Dugel, Rishi P. Singh, Adrian Koh, Yuichiro Ogura, Georges Weissgerber, Kinfemichael Gedif, Glenn J. Jaffe, Ramin Tadayoni, Ursula Schmidt-Erfurth, Frank G. Holz
Summary: The study reported the 96-week outcomes of nAMD patients treated with brolucizumab and aflibercept, showing that brolucizumab was more effective in improving vision and reducing retinal fluid compared to aflibercept. The results from both studies confirmed that the efficacy observed at 48 weeks was maintained at 96 weeks.
Article
Ophthalmology
David M. Brown, Marta Nowik, Emmanuel Bouillaud, and Pravin U. Dugel
Summary: The purpose of this study was to evaluate the efficacy and safety of brolucizumab 6 mg drug product in patients with neovascular age-related macular degeneration, and compare it to the brolucizumab product used in Phase III clinical trials. The results showed that the intended commercial formulation of brolucizumab 6 mg had consistent efficacy and safety with the product used in the Phase III studies.
CURRENT EYE RESEARCH
(2023)
Review
Pharmacology & Pharmacy
Junlan Chuan, Lianqiao Liu, Yumei Feng, Mengdan Wang, Gang Li, Qin Lv
Summary: Through the meta-analysis, it was found that brolucizumab is comparable to other anti-VEGF agents in improving vision and reducing sub-field thickness, but it may lead to more serious ocular adverse events.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Pradeep Kumar Panigrahi
Summary: A 72-year-old male with wet neovascular age related macular degeneration in left eye presented with loss of vision for 1 year. After receiving intravitreal Brolucizumab, there was complete resolution of subretinal fluid and improvement in vision, which was maintained for 3 months with the macula remaining dry.
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
(2021)
Article
Pharmacology & Pharmacy
Andrea Montesel, Claudio Bucolo, Ferenc B. Sallo, Chiara M. Eandi
Summary: This study reports the early efficacy and safety outcomes of treating nAMD with intravitreal injections of brolucizumab. The results showed that brolucizumab was highly effective in restoring anatomy and stabilizing visual acuity, but its safety profile requires further evaluation.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Ophthalmology
Justus G. G. Garweg, Claudine A. A. Blum, Rene-Pierre Copt, Chiara M. M. Eandi, Katja Hatz, Christian F. F. Pruente, Eleonora Seelig, Gabor M. Somfai
Summary: Anti-vascular endothelial growth factor (anti-VEGF) therapies have become standard treatment for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, the need for regular injections is burdensome and long-term vision improvement may not be maintained. Brolucizumab, an intravitreal anti-VEGF therapy, shows potential to decrease injection frequency and provide effective treatment, but there are risks associated with it.
OPHTHALMOLOGY AND THERAPY
(2023)
Article
Ophthalmology
Maiko Maruyama-Inoue, Yasuo Yanagi, Tatsuya Inoue, Kazuaki Kadonosono
Summary: This study compared functional and morphologic changes in the loading phase between patients with treatment-naive macular neovascularization (MNV) due to neovascular age-related macular degeneration (nAMD) treated with intravitreal brolucizumab (IVBr) or intravitreal faricimab (IVF) injections. The results showed that both IVBr and IVF injections improved visual acuity and decreased foveal and choroidal thickness in the loading phase, with IVBr group showing faster visual improvements and greater reductions in thickness.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2023)
Article
Multidisciplinary Sciences
Hoseok Yeom, Hye Ji Kwon, Yoon Jeon Kim, Junyeop Lee, Young Hee Yoon, Joo Yong Lee
Summary: This retrospective study assessed the safety and effectiveness of switching to intravitreal brolucizumab for refractory nAMD. The results showed that the majority of patients experienced improved anatomical outcomes or extended injection intervals after switching. Certain structural biomarkers were identified as predictors of treatment response, aiding in the selection of an appropriate therapeutic strategy.
SCIENTIFIC REPORTS
(2023)
Article
Multidisciplinary Sciences
Hidetaka Matsumoto, Junki Hoshino, Ryo Mukai, Kosuke Nakamura, Hideo Akiyama
Summary: Loading phase treatment with intravitreal brolucizumab may improve visual acuity and reduce exudative changes in eyes with nAMD associated with type 1 CNV, but careful monitoring for brolucizumab-related intraocular inflammation is necessary.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Christof Haensli, Isabel B. Pfister, Justus G. Garweg
Summary: The study aimed to evaluate the effect of switching treatment to brolucizumab in eyes with neovascular age-related macular degeneration with treatment intervals of <= 6 weeks. Results showed improvement in visual performance and longer treatment intervals over 6 months, indicating the potential of brolucizumab to reduce treatment burden in nAMD, despite encountering two cases of intraocular inflammation.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Health Care Sciences & Services
Nicola Ferrante, Daniela Ritrovato, Rossella Bitonti, Gianluca Furneri
Summary: The study evaluated the cost-effectiveness of brolucizumab in treating neovascular AMD, showing its superiority over aflibercept in both base-case and alternative scenarios. Treatment with brolucizumab reduces the economic burden on patients and improves quality-adjusted survival.
BMC HEALTH SERVICES RESEARCH
(2022)
Article
Ophthalmology
Mark R. Barakat, Mark Shusterman, Darius Moshfeghi, Ronald Danis, Michael Gertner, Rishi P. Singh
ARCHIVES OF OPHTHALMOLOGY
(2011)
Article
Genetics & Heredity
Mark R. Barakat, Elias I. Traboulsi, Jonathan E. Sears
OPHTHALMIC GENETICS
(2009)
Article
Ophthalmology
Chen-Rei Wan, Barry Kapik, Charles C. Wykoff, Christopher R. Henry, Mark R. Barakat, Milan Shah, Rafael Andino, Thomas A. Ciulla
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
(2020)
Article
Ophthalmology
Christopher Ryan Henry, Milan Shah, Mark R. Barakat, Pouya Dayani, Robert C. Wang, Rahul N. Khurana, Lana Rifkin, Steven Yeh, Colette Hall, Thomas Ciulla
Summary: The study evaluated the safety of suprachoroidal triamcinolone acetonide injections in patients with non-infectious uveitis. The treatment was found to be safe and well tolerated over the 24-week period.
BRITISH JOURNAL OF OPHTHALMOLOGY
(2022)
Article
Ophthalmology
Rahul N. Khurana, Pauline Merrill, Steven Yeh, Eric Suhler, Mark R. Barakat, Eduardo Uchiyama, Christopher Ryan Henry, Milan Shah, Robert C. Wang, Barry Kapik, Thomas Ciulla
Summary: The suprachoroidal triamcinolone acetonide injectable suspension (CLS-TA) demonstrated extended efficacy and safety in patients with macular edema secondary to non-infectious uveitis, with approximately 50% of patients not requiring additional treatment for up to 9 months following the last administration. This treatment resulted in significant improvements in visual acuity and reduction in retinal central subfield thickness for those patients who did not require rescue therapy. No serious adverse events related to the study treatment were observed, indicating the safety of CLS-TA in this patient population.
BRITISH JOURNAL OF OPHTHALMOLOGY
(2022)
Article
Ophthalmology
Mark P. Breazzano, Archana A. Nair, J. Fernando Arevalo, Mark R. Barakat, Audina M. Berrocal, Jonathan S. Chang, Andrew Chen, Dean Eliott, Sunir J. Garg, Quraish Ghadiali, Dan Gong, Dilraj S. Grewal, James T. Handa, Matthew Henderson, Yannek I. Leiderman, Theodore Leng, Amar Mannina, Thomas A. Mendel, Debarshi Mustafi, Lisa C. Olmos de Koo, Shriji N. Patel, Tapan P. Patel, Jonathan Prenner, Paige Richards, Rishi P. Singh, Charles C. Wykoff, Nicolas A. Yannuzzi, Hannah Yu, Yasha S. Modi, Stanley Chang
Summary: This study found a significant nationwide decrease in urgent or emergent vitreoretinal surgical procedures during the COVID-19 pandemic, which lasted for a period independent of region, practice setting, and state-level stay-at-home orders. The decline suggests a need for ophthalmology practices to prioritize availability for such critical procedures until the reasons behind the decrease are fully understood.
JAMA OPHTHALMOLOGY
(2021)
Article
Ophthalmology
Thomas A. Ciulla, Barry Kapik, Mark R. Barakat, Rahul N. Khurana, Quan Dong Nguyen, Dilraj S. Grewal, Thomas Albini, Emmett T. Cunningham, Debra A. Goldstein
Summary: This study assessed the relationship between BCVA and OCT features in NIU-related macular edema. The results showed that baseline EZ integrity and the presence of central subfield cystoid spaces or subretinal fluid predicted improved therapeutic response. Modeling analysis indicated that CST improvement preceded BCVA improvement in eyes treated with CLS-TA.
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2022)
Article
Ophthalmology
Arshad M. Khanani, Aamir A. Aziz, Hannah Khan, Ashwin Gupta, Ohidul Mojumder, Aigerim Saulebayeva, Ashkan M. Abbey, David R. P. Almeida, Robert L. Avery, Himanshu K. Banda, Mark R. Barakat, Ramanath Bhandari, Emmanuel Y. Chang, Sara J. Haug, Nikolas J. S. London, Luke Mein, Veeral S. Sheth, Jeremy D. Wolfe, Michael A. Singer, Carl J. Danzig
Summary: This study retrospectively analyzed real-world patients receiving faricimab for the treatment of neovascular age-related macular degeneration (nAMD). The results showed that faricimab can improve or maintain visual acuity and rapidly improve anatomical parameters. It was well-tolerated with a low incidence of treatable intraocular inflammation.
Review
Ophthalmology
Charles C. Wykoff, Hidetaka Matsumoto, Mark R. Barakat, Helene Karcher, Anthony Lozama, Andrew Mayhook, Olorunfemi A. Oshagbemi, Olessia Zorina, Tarek S. Hassan, Arshad M. Khanani, Jeffrey S. Heier
Summary: This systematic literature review evaluated the occurrence of retinal vasculitis or vascular occlusion events after treatment with brolucizumab for neovascular age-related macular degeneration. The results showed that most of these events occurred in women in the real-world practice, and about half of the eyes experienced visual acuity loss. Overall, the importance of this study is rated 8 out of 10.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
(2023)
Article
Ophthalmology
Mark R. Barakat, Charles C. Wykoff, Victor Gonzalez, Allen Hu, Dennis Marcus, Eric Zavaleta, Thomas A. Ciulla
Summary: The study evaluated the safety, efficacy, and durability advantages of CLS-TA administered supra-choroidally in conjunction with intravitreal aflibercept for treating DME. Results showed similar visual benefit at 24 weeks' follow-up compared with aflibercept monotherapy, with good tolerability and potential to reduce treatment burden.
OPHTHALMOLOGY RETINA
(2021)
Article
Ophthalmology
Peter A. Campochiaro, Charles C. Wykoff, David M. Brown, David S. Boyer, Mark Barakat, Donna Taraborelli, Glenn Noronha
OPHTHALMOLOGY RETINA
(2018)
Article
Ophthalmology
M. R. Barakat, T. I. Metelitsina, J. C. DuPont, J. E. Grunwald
CURRENT EYE RESEARCH
(2006)
Article
Ophthalmology
AH Milam, MR Barakat, N Gupta, L Rose, TS Aleman, MJ Pianta, AV Cideciyan, VC Sheffield, EM Stone, SG Jacobson
Article
Multidisciplinary Sciences
AH Milam, L Rose, AV Cideciyan, MR Barakat, WX Tang, N Gupta, TS Aleman, AF Wright, EM Stone, VC Sheffield, SG Jacobson
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2002)